Geode Capital Management LLC Has $114.92 Million Stake in Lantheus Holdings, Inc. $LNTH

Geode Capital Management LLC decreased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 1.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,726,521 shares of the medical equipment provider’s stock after selling 27,983 shares during the period. Geode Capital Management LLC’s holdings in Lantheus were worth $114,918,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in shares of Lantheus by 1.7% during the 3rd quarter. Vanguard Group Inc. now owns 6,952,418 shares of the medical equipment provider’s stock valued at $356,590,000 after acquiring an additional 115,338 shares during the last quarter. M&T Bank Corp acquired a new position in shares of Lantheus during the 4th quarter valued at about $370,950,000. TD Asset Management Inc increased its holdings in shares of Lantheus by 25.0% during the 3rd quarter. TD Asset Management Inc now owns 790,950 shares of the medical equipment provider’s stock valued at $40,568,000 after acquiring an additional 158,358 shares during the last quarter. William Blair Investment Management LLC increased its holdings in shares of Lantheus by 46.7% during the 3rd quarter. William Blair Investment Management LLC now owns 574,681 shares of the medical equipment provider’s stock valued at $29,475,000 after acquiring an additional 183,059 shares during the last quarter. Finally, Mackenzie Financial Corp increased its holdings in shares of Lantheus by 0.6% during the 3rd quarter. Mackenzie Financial Corp now owns 501,593 shares of the medical equipment provider’s stock valued at $25,727,000 after acquiring an additional 2,950 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $100.98 on Friday. The business has a 50 day moving average price of $88.01 and a 200 day moving average price of $74.96. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $104.00. The company has a market cap of $6.57 billion, a price-to-earnings ratio of 24.33 and a beta of -0.03. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The company had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. During the same quarter last year, the company earned $1.53 EPS. The company’s quarterly revenue was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Research analysts predict that Lantheus Holdings, Inc. will post 4.42 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Mizuho increased their price objective on Lantheus from $100.00 to $115.00 and gave the company an “outperform” rating in a report on Wednesday, May 27th. JonesTrading lowered Lantheus from a “buy” rating to a “hold” rating in a report on Friday, February 27th. B. Riley Financial restated a “buy” rating on shares of Lantheus in a research note on Friday, May 1st. Citizens Jmp increased their target price on Lantheus from $85.00 to $115.00 and gave the company a “market outperform” rating in a research note on Friday, May 8th. Finally, Citigroup restated an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $101.86.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.